Inhalation Sciences receives US Registered Trademarks for core aerosol technology
(Stockholm, Sweden, 25 November, 2021) Inhalation Sciences AB (ISAB) has received Registered Trademarks in the US for PreciseInhale®, its core aerosol generating system, DissolvIt®, its unique in vitro dissolution module, and XposeALI®, its air-liquid interface cell culturing tool. The US is a strategic target market for ISAB.
The US is the world’s largest and most innovative market for inhaled pharmaceuticals. ISAB’s Labtech product PreciseInhale® significantly reduces risk in inhaled drug development. It is currently being trialled for clinical use in humans, which would offer the unique possibility of directly establishing a correlation between the preclinical and clinical effects of drug substances. In August 2021 ISAB announced that the US patent on PreciseInhale® had been extended until 2034.
ISAB CEO Manoush Masarrat: “The US is a highly dynamic and innovative market, and a priority one for us. This new protection underlines how unique our offering is as we continue to build business and relationships with our partners and prospects in the US.”
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
Tags: